IκBα Antibody

About the Target

MAD3 is a target of interest in many antibody-based workflows. IκBα (Inhibitor of kappa B alpha) is a key cytoplasmic inhibitor of the NF-κB signaling pathway, which regulates genes involved in inflammation, immunity, apoptosis, and cell proliferation. It binds to NF-κB dimers, such as p65/p50, masking their nuclear localization signals and retaining them in an inactive state in the cytoplasm. Depending on the literature source, MAD3 may also be discussed as IkappaBalpha and NF-kappa-B inhibitor alpha; I-kappa-B-alpha; IkB-alpha; IkappaBalpha; Major histocompatibility complex enhancer-binding protein MAD3; NFKBIA; IKBA; MAD3; NFKBI.

Reported cellular context includes cytoplasm and nucleus, which can matter when signal is compared across treatments or changing cell states. Following MAD3 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.

Research Context

MAD3 is commonly interpreted in the context of inflammation and cell signaling research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cytoplasm and nucleus, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

• apparent redistribution between cytoplasm and nucleus across matched conditions
• responses associated with cytokine exposure, inflammatory tone, or tissue stress
• signal-dependent shifts after ligand, inhibitor, or growth-factor perturbation
• co-patterning with orthogonal markers and control conditions that clarify pathway state

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for MAD3. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in MAD3 reflect biology rather than handling. When interpreting MAD3, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep MAD3 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.